COMMUNIQUÉS West-GlobeNewswire

Assertio Holdings, Inc. to Report Third Quarter 2024 Financial Results on November 11, 2024

30/10/2024 - 13:00

LAKE FOREST, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated [...]

LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024

30/10/2024 - 13:00

SAN DIEGO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the [...]

Alignment Health Plan Named a “Best” Medicare Advantage Insurer in North Carolina by U.S. News & World Report for Third Consecutive Year

30/10/2024 - 13:00

HMO retained its 5-star rating for three straight years from Centers for Medicare & Medicaid Services, one of only 7 in country to earn top rating in 2025 RALEIGH, N.C., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Alignment [...]

Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024

30/10/2024 - 13:00

PRINCETON, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, its novel injectable formulation of [...]

Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3

30/10/2024 - 13:00

After successful SEISMiC A and B studies in Early Cardiogenic Shock, SEISMiC C will treat more severe SCAI Stage C cardiogenic shock to complete the assessment of the intended Phase 3 patient population Windtree plans [...]

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

30/10/2024 - 13:00

– Topline data now anticipated in mid first half of 2025 – – Management to host virtual KOL event today to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program for [...]

Spectral AI Announces Last Patient Out in U.S. Burn Pivotal Study at Burn Centers

30/10/2024 - 13:00

Milestone Achievement Supports Planned FDA Submission of DeepView AI ® -Burn in 2025 DALLAS, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial [...]

KFSHRC Leading Healthcare Innovation and Transformation in Saudi Arabia

30/10/2024 - 12:48

RIYADH, Saudi Arabia, Oct. 30, 2024 (GLOBE NEWSWIRE) -- As Saudi Arabia advances its healthcare transformation journey, King Faisal Specialist Hospital & Research Centre (KFSHRC) is reshaping patient care, [...]

Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance

30/10/2024 - 12:30

CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase CAPLYTA’s strong prescription uptake continues: Q3 2024 CAPLYTA total [...]

HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer

30/10/2024 - 12:30

Study done in collaboration with Memorial Sloan Kettering and led by Dr. Winston Wong, Head and Neck Oncologist and Dr. Alan Ho, Chief of the Head and Neck Oncology Service IIT will evaluate eseba-vec in patients who [...]

MacroGenics Announces Leadership Transition

30/10/2024 - 12:30

Scott Koenig, M.D., Ph.D., to step down as President and CEO Board to initiate search process to identify new CEO ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical [...]

CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update

30/10/2024 - 12:30

‒ Q3 2024 Net Revenue of $11.5 million ‒ ‒ Commercializing DefenCath with Four of Top Five US Dialysis Providers ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., Oct. 30, 2024 [...]

EAACI Unveils Groundbreaking Guidelines for IgE-Mediated Food Allergy Management

30/10/2024 - 12:26

New evidence-based approach to food allergy management ZÜRICH, Oct. 30, 2024 (GLOBE NEWSWIRE) -- The European Academy of Allergy and Clinical Immunology (EAACI) has released the updated “Clinical Guidelines on the [...]

RTI Surgical celebrates expansion of Tutoplast® Tissue Sterilization Process facility

30/10/2024 - 12:17

Ribbon-cutting ceremony to take place today, in Alachua, Florida ALACHUA, Fla., October 30, 2024 ; RTI Surgical ("RTI" or "the Company"), a leading CDMO pushing the boundaries of innovation and tissue engineering to [...]

eLabNext Launches New Brand Positioning with Centralized Digital Lab Platform

30/10/2024 - 12:09

GRONINGEN, The Netherlands, Oct. 30, 2024 (GLOBE NEWSWIRE) -- eLabNext , a leading provider of digital lab management solutions, is proud to announce a major shift in its brand positioning, consolidating its three [...]

SynOx Therapeutics Adds New Investor and Capital to Series B Financing, Raising Total to $92 Million, and Doses First Patients in Phase 3 Trial

30/10/2024 - 12:00

Gilde Healthcare Leads Series B Extension, Joining Premier Syndicate of Leading Life Science Investors Funding Supports Registrational Phase 3 TANGENT Trial of Emactuzumab, a Best-in-Class CSF-1 Receptor Targeted [...]

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

30/10/2024 - 12:00

– On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be presented at San Antonio [...]

Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

30/10/2024 - 12:00

BOSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for [...]

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

30/10/2024 - 12:00

Nomlabofusp program update expected mid-December to include available safety, pharmacokinetic (PK) and frataxin data, as well as available clinical outcomes observations from patients with Friedreich’s ataxia (FA) [...]